Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Erratum: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (Clin Cancer Res (2021) 27 (5236-5247)DOI: 10.1158/1078-0432.CCR-21-0715)'. Together they form a unique fingerprint.

Medicine & Life Sciences